The molecular genetics of astrocytomas: Current understanding and future applications

Journal of Clinical Neuroscience

Volumn 4, Issue 2, 1997, Pages 114-121

  Walker, David G ^a   Lavin, Martin F ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Astrocytoma; Genetics; Oncogene; Review; Tumour suppressor gene

Indexed keywords

EID: 0007056254     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0967-5868(97)90060-6     Document Type: Review

References (110)

1. Rey JA, Pestana A, Bello MJ. Cytogenetics and molecular genetics of nervous system tumors. Oncology Res 1992; 4: 321-331.
2. Sandberg AA. The Chromosomes in Human Cancer and Leukemia, 2nd edn. New York: Elsevier, 1990.
3. Bello MJ, de Campos JM, Kusak ME, et al. Molecular analysis of genomic abnormalities in human gliomas. Cancer Genet Cytogenet 1993; 73: 122-129.
4. Mapstone T, McMichael M, Goldthwait D. Expression of platelet-derived growth factors, transforming growth Factors, and the ros gene in a variety of primary human brain tumors. Neurosurgery 1991; 28: 216-222.
5. Hermansson M, Nister M, Betsholz C, Heldin CH, Westermark B, Funa K. Endothelial cell hyperplasia in human glioblastoma: Coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation. Proc Natl Acad Sci USA 1988; 85: 7748-7752.
6. Chaffanet M, Chauvin C, Laine M, et al. EGF receptor amplification and expression in human brain tumors. Eur J Cancer 1992; 28: 11-17.
7. Lund-Hohansen M, Forsberg K, Bjerkvig R, Laerum OD. Effects of growth factors on a human glioma cell line during invasion into rat brain aggregates in culture. Acta Neuropathol 1992; 84: 190-197.
8. Chicoine MR, Madsen CL, Silbergeld DL. Modification of human glioma locomotion in vitro by cytokines EGF, bFGF, PDGFbb, NGF and TNF-alpha. Neurosurgery 1995; 36: 1165-1170.
9. Merzak A, Koochekpour S, Dkhisssi F, Raynal S, Lawrence D, Pilkington GJ. Synergism between growth factors in the control of glioma cell proliferation, migration and invasion in vitro. International J Oncol 1995; 6: 1079-1085.
10. Paulus W, I. B, Huettner C, Schmausser B, Roggendorf W, Schlingensiepen KH. Effects of transforming growth factor-beta (1) on collagen synthesis, integrin expression, adhesion and invasion of glioma cells. J Neuropath Exp Neurol 1995; 54: 236-244.
11. Sandberg AC, Engberg C, Lake M, von Holst H, Sara VR. The expression of insulin-like growth factor I and insulin-like growth factor II genes in the human fetal and adult brain and in gliomas. Neurosci Lett 1988; 93: 114-119.
12. Antoniades HN, Galanopoulis T, Nevile-Golden J, Maxwell M. Expression of insulin-like growth factors I and II and their receptor mRNAs in primary human astrocytomas and meningiomas: In vivo studies using in situ hybridization and immunocytochemistry. Int J Cancer 1992; 50: 215-222.
13. Sandberg-Nordqvist A, Stahlbom P, Reinecke M, Collins VP, von Holst H, Sara V. Characterization of insulin-like growth factor 1 in human primary brain tumors. Cancer Res 1993; 53: 2475-2478.
14. Paulus W, Grothe C, Sensenbrenner M, Janet T, Graf M, Roggendorf W. Localization of basic fibtroblast growth factor, a mitogen and angiogenic factor, in human brain tumors. Acta Neuropathol 1990; 79: 418-423.
15. Plate K, Breier G, Risau W. Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol 1994; 4: 207-218.
16. Redekop GJ, Naus CCG. Transfection with bFGF sense and antisense cDNA resulting in modification of malignant glioma growth. J Neurosurg 1995; 82: 83-90.
17. Bongcam-Rudloff E, Nister M, Betsholtz C, et al. Human glial fibrillary acidic protein: complementary DNA cloning, chromosome localization, and messenger RNA expression in human glioma cell lines of various phenotypes. Cancer Res 1991; 51: 1553-1560.
18. Merrill MJ, Edwards NA. Insulin-like growth factor-1 receptors in human glial tumors. J Clin Endocrinol Metab 1990; 71: 199-209.
19. Fischer U, Muller HW, Sattler HP, Feiden K, Zang KD, Meese E. Amplification of the MET gene in glioma. Genes Chrom Cancer 1995; 12: 63-65.
20. Hurtt MR, Moossy J, Donovan-Peluso M, Locker J. amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J Neuropath Exp Neurol 1992; 51: 84-90.
21. Gerosa MA, Talarico D, Fognani C, et al. Overexpression of N-ras oncogene and epidermal growth factor receptor gene in human glioblastomas. J Natl Cancer Inst 1989; 81: 63-67.
22. Orian JM, Vasilopoulos K, Yoshida S, Kaye AH, Chow CW, Gonzales MF. Overexpression of multiple oncogenes related to histological grade of astrocytic glioma. Br J Cancer 1992; 66: 106-112.
23. Patt S, Thiel G, Maas S, et al. Chromosomal changes and correspondingly altered proto-oncogene expression in human gliomas. Value of combined cytogenetic and molecular genetic analysis. Anticancer Res 1993; 13: 113-118.
24. He J, Allen JR, Collins VP, et al. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 1994; 54: 5804-5807.
25. INK4 expression is frequent in high grade gliomas. Cancer Res 1995; 55: 1941-1945.
26. Welter C, Henn W, Theisinger B, Fischer H, Zang KD, Blin N. The cellular myb oncogene is amplified, rearranged and activated in human glioblastoma cell lines. Cancer Lett 1990; 52: 57-62.
27. Kinzler KW, Ruppert JM, Bigner SH, Vogelstein B. The GLI gene is a member of the Kruppel family of zinc finger proteins. Nature 1988; 332: 371-374.
28. Burgart LJ, Robinson RA, Haddad SF, Moore SA. Oncogene abnormalities in astrocytomas: EGFR gene alone appears to be more frequently amplified and rearranged compared with other protooncogenes. Mod Pathol 1991; 4: 183-186.
29. Liberman TA, Nusbaum HR, Razon N, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary brain tumors of glial origin. Nature 1985; 313: 144-147.
30. Schwechheimer K, Huang S, Cavenee WK. EGFR gene amplification-rearrangement in human glioblastomas. Int J Cancer 1995; 62: 145-148.
31. Humphrey PA, Gangarosa AJ, Wong AJ, et al. Deletion-mutant epidermal growth factor receptor in human gliomas: effect of type II mutation on receptor function. Biochem Biophys Res Comm 1991; 178: 1413-1420.
32. Yamakazi H, Ohba Y, Tamaoki N, et al. A deletion mutation within the ligand binding domian is responsible for activation of the epidermal growth factor receptor gene in human brain tumours. Jpn J Cancer Res 1990; 81: 773-779.
33. Bigner SH, Mark J, Burger RC, et al. Specific chromosomal abnormalities in malignant human gliomas. Cancer Res 1988; 405-411.
34. Schlegel J, Merdes A, Stumm G, et al. Amplification of the epidermal growth factor receptor gene correlates with different growth behaviours in human glioblastoma. Int J Cancer 1994; 56: 72-77.
35. Brady LW, Miyamot OC, Woo DV, et al. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody against epidermal growth factor receptor: a phase II trial. J Rad Oncol Biol Phys 1992; 22: 225-230.
36. Dadparvar S, Krishna L, Miyamoto C, et al. Indium-111-labeled anti-EGFr-425 scintigraphy in the detection of malignant gliomas. Cancer 1994; 73: 884-889.
37. Kim DH, Mohapatra G, Bollen A, Waldman FM, Feuerstein BG. Chromosomal abnormalities in glioblastoma multiforme tumors and glioma cell lines detected by comparative genomic hybridization. Int J Cancer 1995; 60: 812-819.
38. Reifenberger G, Reifenberger J, Ichimura K, Collins VP. Amplification at 12q13-14 in human malignant gliomas is frequently accompanied by loss of heterozygosity at loci proximal and distal to the amplification site. Cancer Res 1995; 55: 731-734.
39. James CD, Collins VP. Glial tumors. In: Levine AJ, Schmidek HH (eds). Molecular Genetics of Nervous System Tumors. New York: Wiley-Liss, 1993: 249-254.
40. Hunter T, Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573-582.
41. Frankel RH, Bayona W, Koslow M, Newcomb EW. p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. Cancer Res 1992; 52: 1427-1433.
42. Saxena A, Clark WC, Robertson JT, Ikejiri B, Oldfield EH, Ali IU. Evidence for the involvement of a potential second tumor suppressor gene in chromosome 17 distinct from p53 in malignant astrocytomas. Cancer Res 1992; 52: 6716-67121.
43. von Deimling A, Eibl RH, Ohgaki H, et al. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 1992; 52: 2987-2990.
44. El-Diery WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
45. Louis DN. The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 1994; 53: 11-21.
46. Louis DN, von Deimling A, Chung RY, et al. Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropath Exp Neurol 1993; 52: 31-38.
47. Rasheed BKA, McLendon RE, Herndon JE, et al. Alterations of the TP53 gene in human gliomas. Cancer Res 1994; 54: 1324-1330.
48. Chozick BS, Pezullo JC, Epstein MH, Finch PW. Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery 1994; 35: 831-837.
49. Alsarraj A, Bridges LR. p53 immunoreactivity in astrocytomas and its relationship to survival. Br J Neurosurg 1995; 9: 143-149.
50. Danks RA, Chopra G, Gonzales MF, Orian JM, Kaye AH. Aberrant p53 expression does not correlate with the prognosis in anaplastic astrocytoma. Neurosurgery 1995; 37: 246-254.
51. Srivastava S, Zou Z, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990; 383: 747-749.
52. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990; 250: 1222-1224.
53. Lubbe J, von Ammon K, Watanabe K, Hegi M, Kleihaus P. Familial brain tumour syndrome associated with a p53 germline deletion of codon 236. Brain Pathol 1995; 5: 15-23.
54. Olopade OI, Jenkins RB, Ransom DT, et al. Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. Cancer Res 1992; 52: 2523-2529.
55. Coleman A, Fountain JW, Nobori T, et al. Distinct deletions of chromosome 9p associated with melanoma versus glioma, lung cancer; and leukemia. Cancer Res 1994; 54: 344-348.
56. Fountain JW, Karayiourgou M, Ernstoff MS, et al. Homozygous deletions within human chromosome band 9p21 in melanomas. Proc Natl Acad Sci USA 1992; 89: 10557-10561.
57. Olopade OI, Buchhagen DL, Malik K, et al. Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res 1993; 53: 2410-2415.
58. Cheng JQ, Jhanwar SC, Klein WM, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994; 54: 5547-5551.
59. Stadler WM, Sherman J, Bohlander SK, et al. Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer. Cancer Res 1994; 54: 2060-2063.
60. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-440.
61. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753-756.
62. Giani C, Finocchiaro G. Mutation rate of the CDKN2 gene in malignant gliomas. Cancer Res 1994; 54: 6338-6339.
63. Jen J, Harper JW, Bigner SH, et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res 1994; 54: 6353-6358.
64. Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994; 54: 6321-6324.
65. Walker DG, Duan W, Popovic EA, Kaye AH, Tomlinson FH, Lavin M. Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas. Cancer Res 1995; 55: 20-23.
66. Gomi A, Sakai R, Ogawa S, Shinoda S, Hirai H, Masuzawa T. Frequent loss of the cyclin-dependent kinase-4 inhibitor gene in human gliomas. Jpn J Cancer Res 1995; 86: 342-346.
67. Moulton T, Samara G, Chung WY, et al. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol 1995; 146: 613-619.
68. INK4A transcript. Cancer Res 1995; 55: 2995-2997.
69. Stone S, Jiang P, Dayananth P, et al. Complex structure and regulation of the p16 (MTS1) locus. Cancer Res 1995; 55: 2988-2994.
70. Serrano M, Hannon GJ, Beach DB. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-707.
71. Bates S, Peters G. Cyclin D1 as a cellular proto-oncogene. Semin Cancer Biol 1995; 6: 73-82.
72. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J-Y, Livingstone DM. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 1993; 73: 487-497.
73. Muller R. Transcriptional regulation during the mammalian cell cycle. TIG 1995; 11: 173-178.
74. INK4B/MTS2- related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994; 8: 2939-2952.
75. Hirai H, Roussel MF, Kato JY, Ashmun RA, Sherr CJ. Novel ink4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 1995; 15: 2672-2681.
76. von Deimling A, Nagel J, Bender B, et al. Deletion mapping of chromosome 19 in human gliomas. Int J Cancer 1994; 57: 676-680.
77. Kraus JA, Koopman J, Kaskel P, et al. Shared allelic losses on chromosome 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropath Exp Neurol 1995; 54: 91-95.
78. Ritland SR, Ganju V, Jenkins RB. Region-specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma. Genes Chrom Cancer 1995; 12: 277-282.
79. Henson JW, Schnitket BL, Correa KM, et al. The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol 1994; 36: 714-721.
80. Rasheed BKA, McLendon RE, Friedman HS, et al. Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene 1995; 10: 2243-2246.
81. Collins VP, James CD. Gene and chromosomal alterations associated with the development of human gliomas. FASEB J 1993; 7: 926-930.
82. Dalrymple SJ, Herath JF, Ritland SR, Moertel CA, Jenkins RB. Use of fluorescence in situ hybridization to detect loss of chromosome 10 in astrocytomas. J Neurosurg 1995; 83: 316-323.
83. Albarosa R, Didonato S, Finocchiaro G. Redefinition of the coding sequence of the MXI1 gene and identification of a polymorphic repeat in the 3' non-coding region that allows the detection of loss of heterozygosity of chromosome 10q25 in glioblastomas. Hum Genetics 1995; 95: 709-711.
84. Pilkington G. Tumour cell migration in the central nervous system. Brain Pathol 1994; 4: 157-166.
85. Berens ME, Giese A, Hasken D, Coons SW. Dichotomy of astrocytoma migration and proliferation. Proc Am Assoc Cancer Res 1995; 36: 68.
86. Liotta LA. Tumor invasion and metastases - role of the extracellular matrix. Cancer Res 1986; 46: 1-7.
87. Li H, Hamou M, de Tribolet N, et al. Variant CD44 adhesion molecules are expressed in human brain metastases but not in glioblastomas. Cancer Res 1993; 53: 5345-5349.
88. Okada H, Yoshida J, Seo H, Wakabayashi T, Sugita K, Hagiwara M. Anti-(glioma surface antigen) monoclonal antibody G-22 recognizes overexpressed CD44 in glioma cells. Cancer Immunol Immunother 1995; 39: 313-317.
89. Radotra B, McCormick D, Crockard A. CD44 plays a role in adhesive interactions between glioma cells and extracellular matrix components. J Neuropath Appl Neurobiol 1994; 20: 399-405.
90. Apodaca G, Rutka TJ, Bouhana K, et al. Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Res 1990; 50: 2322-2329.
91. Nakano A, Tani E, Miyazaki K, Furuyama J, Matsumoto T. Expressions of matrilysin and stromelysin in human glioma cells. Biochem Biophys Res Comm 1993; 192: 999-1003.
92. Rao JS, Steck PA, Mohanam S, Stetler-Stevenson WG, Liotta LA, Sawaya R. Elevated levels of Mr 92, 000 type IV collagenase in human brain tumors. Cancer Res 1993; 53: 2208-2211.
93. Rucklidge GJ, Lund-Johansen M, Milne G, Bjerkvig R. Isolation and characterization of a metalloproteinase secreted by rat glioma cells in serum-free culture. Biochem Biophys Res Comm 1990; 172: 544-550.
94. Nakano A, Tani E, Miyazaki K, Yamamoto Y, Furuyama J. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J Neurosurg 1995; 83: 298-307.
95. Mikkelsen T, Spencer D, Nelson K, Rasnick D, Rosenblum ML. Novel cysteine protease inhibitors in the control of glioma cell migration. Proc Am Assoc Cancer Res 1995; 36: 99.
96. Burger PC, Scheithauer BW. Tumors of the Central Nervous System, 3rd edn. Washington DC: Armed Forces Institute of Pathology, 1994.
97. Stefanik DF, Rizkalla LR, Soi A, Goldblatt SA, Rizkalla WM. Acidic and basic fibroblast growth factor are present in glioblastoma multiforme. Cancer Res 1991; 51: 5760-5765.
98. Plate KH, Breier G, Millauer B, Ullrich B, Risau W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 1993; 53: 5822-5827.
99. Plate KH, Breier G, Weich HA, Mennel HD, Risau W. Vascular endothelial growth factor and glioma angiogenesis - coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 1994; 59: 520-529.
100. Samoto K, Ikezaki K, Ono M, et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 1995; 55: 1189-1193.
101. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 359: 845-848.
102. Philips HS, Armani MP, Stavrou D, Ferrara N, Westphal M. Intense focal expression of vascular endothelial growth factor mRNA in human intracranial neoplasms: association with regions of necrosis. Int J Oncol 1993; 31: 13-20.
103. Kieser A, Weich HA, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase c induction of vascular endothelial growth factor. Oncogene 1994; 9: 963-969.
104. Van Meir EG, Polverini PJ, Chazin VR, Su Huang H-J, de Tribolet N, Cavenee WK. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nature Genet 1994; 8: 171-176.
105. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993; 3: 19-26.
106. Lang FF, Miller DC, Koslow M, Newcomb EW. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 1994; 81: 427-436.
107. van Meyel DJ, Ramsay DA, Casson AG, Keeney M, Chambers AF, Cairncross JG. p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. J Natl Cancer Inst 1994; 86: 1011-1017.
108. Jones CE, Davis MB, Darling JL, Geddes JF, Thomas DGT, Harding AE. Loss of heterozygosity for DNA polymorphisms mapping to chromosomes 10 and 17 and prognosis in patients with gliomas. J Neurol Neurosurg Psychiatry 1995; 58: 218-221.
109. Coons SW, Johnson PC, Rankin Shapiro J. Cytogenetic and flow cytometry dna analysis of regional heterogeneity in a low grade human glioma. Cancer Res 1995; 55: 1569-1577.
110. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavenee WBV. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 1992; 355: 846-847.